The 2026 update from the Global Initiative for Asthma (GINA) places increased emphasis on asthma-related cough by expanding and clarifying guidance on its role in diagnosis, differential diagnosis, and overall assessment. The update broadens the guideline’s coverage of cough, reflecting heightened global clinical and research attention to cough as an important asthma manifestation.
GINA 2026 refines the characterization of cough-related asthma phenotypes, offering more detailed phenotypic distinctions for presentations in which cough is a dominant symptom. These refinements are intended to help clinicians recognize patterns of airway disease where cough may drive diagnostic and management decisions, and to align phenotype descriptions with contemporary research and clinical observations.
A notable methodological change in GINA 2026 is the inclusion of induced sputum differential cell analysis as a diagnostic tool for asthma. By incorporating sputum cytology into the diagnostic armamentarium, the update acknowledges a role for objective airway inflammatory assessment beyond standard measures. The guideline positions induced sputum differential cell counts as an additional diagnostic method that can inform phenotype classification and potentially guide treatment choices based on inflammatory cell profiles.
The 2026 GINA update explicitly incorporates chronic cough–related etiologies into the differential diagnosis when evaluating patients with suspected asthma. This change emphasizes the importance of systematically considering nonasthma causes of chronic cough and ensuring that clinicians differentiate asthma from other conditions that can present predominantly with cough. The explicit inclusion of chronic cough etiologies aims to reduce misdiagnosis and to direct clinicians toward appropriate investigations when cough is the chief complaint.
GINA 2026 integrates cough symptoms into routine asthma assessment, reinforcing that cough is a clinically meaningful symptom that should be evaluated when determining asthma control and severity. Incorporating cough into assessment frameworks supports more comprehensive monitoring of symptom burden and may influence decisions about treatment escalation, phenotype-directed therapy, or additional diagnostic workup.
The expanded attention to cough within GINA 2026 reflects a broader, growing global focus on cough as it relates to asthma. The update also highlights GINA’s recognition of research contributions from China in the domain of asthma-related cough, indicating that recent evidence and clinical experience from Chinese investigators were considered in shaping the guideline’s revisions.
Clinicians should note the following practice-relevant points from GINA 2026 as reported:
Consider refined cough-related asthma phenotypes when evaluating patients whose primary presentation includes cough, and use phenotype distinctions to inform diagnostic and therapeutic decisions.
Use induced sputum differential cell analysis where available as an adjunctive diagnostic method to assess airway inflammation and to help classify inflammatory phenotypes.
Systematically evaluate chronic cough etiologies during the differential diagnosis of suspected asthma to avoid overlooking alternative causes of persistent cough.
Include cough as a standard element of asthma assessment to better capture symptom burden and to support individualized management strategies.
These implications aim to improve diagnostic accuracy and patient-centered assessment when cough is a prominent feature of a patient’s respiratory presentation.
The summary and commentary on these GINA 2026 updates were reported by K F Lai and F Yi in Zhonghua Jie He He Hu Xi Za Zhi (2026 Sep 12;49(9):921-923), DOI: 10.3760/cma.j.cn112147-20260514-00275. The authors declared no conflicts of interest. The PubMed record includes an English abstract and confirms MeSH indexing terms such as Asthma/diagnosis, Chronic Cough, and Sputum/cytology.
Note: The content in this document is limited to the points reported in the referenced PubMed abstract and related PubMed metadata. Details beyond those summarized in the source (for example, specific phenotype definitions, numeric thresholds for sputum cell counts, or stepwise management changes) were not reported in the abstract and therefore are not included here.